ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2025
Left atrial functional remodeling following percutaneous closure of atrial septal defect secundum in adult patients.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial septal defect secundum (ASDs) is one of the congenital heart diseases that is common in adults and frequently associated with volume overload and functional impairment of the right heart. Percutaneous device closure has become the preferred treatment because of its efficacy and lower complication rates. While right heart remodeling post-closure is well established, the effects on left atrial (LA) function, especially phasic components involving reservoir, conduit, and contraction strain, remain less understood. Two-dimensional speckle tracking echocardiography (2D STE) enables early and sensitive detection of LA functional changes.
methodThis retrospective cohort study included adult patients (aged 18–65 years) with ASDs who underwent percutaneous device closure between December 2022 and October 2023 at Dr. Sardjito Hospital, Yogyakarta, Indonesia. Echocardiographic evaluations, including LA strain analysis (LASr, LAScd, LASc), were performed pre-closure, within 6 months (1st semester), and between ≥ 6–12 months (2nd semester) post-device closure. Patients with significant valvular disease, persistent arrhythmias, or suboptimal acoustic windows were excluded. Statistical analysis was conducted using repeated measures ANOVA or Friedman tests with Bonferroni correction.
resultA total of 21 patients (mean age 40.86 ± 14.74 years; 76% female) were included. LA reservoir strain (LASr) significantly declined in the 1st semester post-device closure compared to baseline (p = 0.003) and showed partial recovery by the 2nd semester (p = 0.016 vs. baseline). LA conduit strain (LAScd) and contraction strain (LASc) also significantly decreased in the 1st semester (p = 0.030 and p = 0.025, respectively), while LASc did not significantly improve at the 2nd semester follow-up. No significant changes were observed in LA geometry. Interobserver agreement for all strain measurements was excellent (ICC ≥ 0.99).
conclusionLA functional impairment was observed in the 1st semester after percutaneous device closure, marked by a noticeable decline in all strains of the LA (LASr, LAScd, and LASc). Partial recovery of LASr was observed at one year, whereas LASc did not show significant improvement after the initial reduction. These findings highlight that the LA strain may be a sensitive marker for predicting the development of LA dysfunction post-device closure follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.